174 related articles for article (PubMed ID: 34294370)
1. Resolvins as potential candidates for the treatment of major depressive disorder.
Deyama S; Minami M; Kaneda K
J Pharmacol Sci; 2021 Sep; 147(1):33-39. PubMed ID: 34294370
[TBL] [Abstract][Full Text] [Related]
2. [Elucidation of the Mechanisms Underlying the Rapid Antidepressant Actions of Ketamine and Search for Possible Candidates for Novel Rapid-acting Antidepressants].
Deyama S
Yakugaku Zasshi; 2023; 143(9):713-720. PubMed ID: 37661437
[TBL] [Abstract][Full Text] [Related]
3. [Resolvins as novel targets for rapid-acting antidepressants].
Deyama S
Nihon Yakurigaku Zasshi; 2020; 155(6):381-385. PubMed ID: 33132254
[TBL] [Abstract][Full Text] [Related]
4. Resolution of depression: antidepressant actions of resolvins.
Deyama S; Kaneda K; Minami M
Neurosci Res; 2022 Oct; ():. PubMed ID: 36272561
[TBL] [Abstract][Full Text] [Related]
5. Resolvin E1/E2 ameliorate lipopolysaccharide-induced depression-like behaviors via ChemR23.
Deyama S; Shimoda K; Suzuki H; Ishikawa Y; Ishimura K; Fukuda H; Hitora-Imamura N; Ide S; Satoh M; Kaneda K; Shuto S; Minami M
Psychopharmacology (Berl); 2018 Jan; 235(1):329-336. PubMed ID: 29090333
[TBL] [Abstract][Full Text] [Related]
6. Intranasal Administration of Resolvin E1 Produces Antidepressant-Like Effects via BDNF/VEGF-mTORC1 Signaling in the Medial Prefrontal Cortex.
Deyama S; Aoki S; Sugie R; Fukuda H; Shuto S; Minami M; Kaneda K
Neurotherapeutics; 2023 Mar; 20(2):484-501. PubMed ID: 36622634
[TBL] [Abstract][Full Text] [Related]
7. N-Methyl-D-aspartate receptor antagonist d-methadone produces rapid, mTORC1-dependent antidepressant effects.
Fogaça MV; Fukumoto K; Franklin T; Liu RJ; Duman CH; Vitolo OV; Duman RS
Neuropsychopharmacology; 2019 Dec; 44(13):2230-2238. PubMed ID: 31454827
[TBL] [Abstract][Full Text] [Related]
8. Resolvin D1 and D2 Reverse Lipopolysaccharide-Induced Depression-Like Behaviors Through the mTORC1 Signaling Pathway.
Deyama S; Ishikawa Y; Yoshikawa K; Shimoda K; Ide S; Satoh M; Minami M
Int J Neuropsychopharmacol; 2017 Jul; 20(7):575-584. PubMed ID: 28419244
[TBL] [Abstract][Full Text] [Related]
9. Role of mTOR1 signaling in the antidepressant effects of ketamine and the potential of mTORC1 activators as novel antidepressants.
Kato T
Neuropharmacology; 2023 Feb; 223():109325. PubMed ID: 36334763
[TBL] [Abstract][Full Text] [Related]
10. Activity-dependent brain-derived neurotrophic factor signaling is required for the antidepressant actions of (2
Fukumoto K; Fogaça MV; Liu RJ; Duman C; Kato T; Li XY; Duman RS
Proc Natl Acad Sci U S A; 2019 Jan; 116(1):297-302. PubMed ID: 30559184
[TBL] [Abstract][Full Text] [Related]
11. The antidepressant-like effect of resolvin E1 in repeated prednisolone-induced depression model mice.
Aoki S; Deyama S; Sugie R; Ishimura K; Fukuda H; Shuto S; Minami M; Kaneda K
Behav Brain Res; 2022 Feb; 418():113676. PubMed ID: 34801580
[TBL] [Abstract][Full Text] [Related]
12. Rapid and sustained antidepressant effects of resolvin D1 and D2 in a chronic unpredictable stress model.
Ishikawa Y; Deyama S; Shimoda K; Yoshikawa K; Ide S; Satoh M; Minami M
Behav Brain Res; 2017 Aug; 332():233-236. PubMed ID: 28610917
[TBL] [Abstract][Full Text] [Related]
13. Resolvin D2 is a potent endogenous inhibitor for transient receptor potential subtype V1/A1, inflammatory pain, and spinal cord synaptic plasticity in mice: distinct roles of resolvin D1, D2, and E1.
Park CK; Xu ZZ; Liu T; Lü N; Serhan CN; Ji RR
J Neurosci; 2011 Dec; 31(50):18433-8. PubMed ID: 22171045
[TBL] [Abstract][Full Text] [Related]
14. Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions.
Xu ZZ; Zhang L; Liu T; Park JY; Berta T; Yang R; Serhan CN; Ji RR
Nat Med; 2010 May; 16(5):592-7, 1p following 597. PubMed ID: 20383154
[TBL] [Abstract][Full Text] [Related]
15. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
[TBL] [Abstract][Full Text] [Related]
16. Molecular and Cellular Mechanisms of Rapid-Acting Antidepressants Ketamine and Scopolamine.
Wohleb ES; Gerhard D; Thomas A; Duman RS
Curr Neuropharmacol; 2017; 15(1):11-20. PubMed ID: 26955968
[TBL] [Abstract][Full Text] [Related]
17. Anti-angiogenesis effect of the novel anti-inflammatory and pro-resolving lipid mediators.
Jin Y; Arita M; Zhang Q; Saban DR; Chauhan SK; Chiang N; Serhan CN; Dana R
Invest Ophthalmol Vis Sci; 2009 Oct; 50(10):4743-52. PubMed ID: 19407006
[TBL] [Abstract][Full Text] [Related]
18. Resolvins AT-D1 and E1 differentially impact functional outcome, post-traumatic sleep, and microglial activation following diffuse brain injury in the mouse.
Harrison JL; Rowe RK; Ellis TW; Yee NS; O'Hara BF; Adelson PD; Lifshitz J
Brain Behav Immun; 2015 Jul; 47():131-40. PubMed ID: 25585137
[TBL] [Abstract][Full Text] [Related]
19. Implications for eicosapentaenoic acid- and docosahexaenoic acid-derived resolvins as therapeutics for arthritis.
Souza PR; Norling LV
Eur J Pharmacol; 2016 Aug; 785():165-173. PubMed ID: 26165764
[TBL] [Abstract][Full Text] [Related]
20. Ketamine: A tale of two enantiomers.
Jelen LA; Young AH; Stone JM
J Psychopharmacol; 2021 Feb; 35(2):109-123. PubMed ID: 33155503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
